a Department for Congenital disorders , State Serum Institute , Copenhagen , Denmark.
b Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology , University of Copenhagen , Copenhagen , Denmark.
Expert Rev Vaccines. 2017 Apr;16(4):329-336. doi: 10.1080/14760584.2017.1276833. Epub 2017 Jan 9.
Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45. Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies. Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.
疟疾是一种由疟原虫引起的毁灭性的虫媒传染病，每年导致近 50 万人死亡。寄生虫有一个复杂的生命周期，包括在人类红细胞中的无性繁殖，导致有症状的疟疾，以及有性阶段，这是传播给蚊子媒介所必需的。针对寄生虫有性阶段的疫苗，从而阻断传播，将是消除疟疾的重要手段。有性阶段抗原 Pfs48/45 是主要的传播阻断疫苗候选物之一。涵盖领域：为了审查基于 Pfs48/45 的亚单位疫苗临床开发的进展和未来前景，我们在 PubMed 上进行了检索。我们将重点关注生物学功能、自然获得的免疫力、特异性抗体的功能活性、序列多样性、重组蛋白的生产和临床前研究。专家评论：Pfs48/45 是一种主要的传播阻断疫苗候选物，应该在临床试验中进一步探索。
